hCG alone normalized testosterone in hypogonadotropic men

How is hCG supposed to protect the testes during TRT?

hCG binds the same LH receptor on Leydig cells and can substitute for the pituitary LH signal that exogenous testosterone suppresses, at least for local testosterone output ^[2].

Exogenous testosterone raises circulating androgen enough to suppress the hypothalamic-pituitary-gonadal axis. GnRH pulses slow, pituitary LH and FSH secretion drop, and without LH signaling the Leydig cells stop generating the very high local testosterone concentration that spermatogenesis depends on. Intratesticular testosterone normally runs far above blood testosterone, and that gradient collapses once LH disappears.

The LH-substitution part of the story is receptor pharmacology, not speculation. Peptides that act further up the same axis are covered in the gonadorelin evidence review and the kisspeptin evidence review.

Does hCG keep intratesticular testosterone up on TRT?

Among the trials cited below, the direct data on hCG sustaining intratesticular testosterone come from men with hypogonadotropic hypogonadism given hCG as gonadotropin replacement, not from men on injectable testosterone.

In a randomized pilot study in that population, a comparatively low hCG dose of 500 IU three times weekly supported intratesticular testosterone sufficient for spermatogenesis in most treated men ^[6]. A much higher conventional dose of 2000 IU three times weekly added no benefit ^[6].

The result supports the general principle that submaximal LH-receptor stimulation is enough, and that more hCG is not automatically better past a threshold. The men in that trial were gonadotropin-deficient before treatment started, a meaningfully different starting physiology from men already suppressed by exogenous testosterone.

Does hCG prevent testicular shrinkage on TRT?

hCG grows testicular volume in hypogonadal men, so preventing shrinkage on TRT is a reasonable extrapolation, but it is still an extrapolation.

A randomized comparison of GnRH pulse therapy against combined hCG and human menopausal gonadotropin found significant increases in both testosterone and testicular volume by six months in the hCG-based arm ^[7]. That is volume recovery from a hypogonadal, sometimes prepubertal-onset baseline. It is not volume maintenance in a man whose testes functioned normally before he started testosterone.

Does hCG preserve fertility during testosterone therapy?

hCG's fertility benefit on TRT is unproven, because the frequently cited gonadotropin success rates come from hypogonadotropic men starting from azoospermia or near it ^[3]. Most consumer coverage never states that gap plainly.

Gonadotropin therapy restores detectable spermatogenesis in roughly 75% of men with hypogonadotropic hypogonadism, with pooled mean concentrations near 5.9 million/mL ^[3]. Those men were rebuilding sperm production, not trying to keep spermatogenesis running while taking suppressive testosterone doses. Outcomes were worse when hypogonadism began before puberty, which underscores how much baseline testicular development shapes the numbers ^[3].

None of those figures answers whether adding hCG to an ongoing testosterone regimen prevents the sperm-count decline that testosterone alone produces. The fertility figures cited for hCG do not come from a randomized comparison of testosterone plus hCG against testosterone alone, with pregnancy rates or semen parameters as the outcome.

Can hCG restore sperm production by itself?

In hypogonadotropic men pooled across four trials, hCG alone restored testosterone but not sperm production; sperm appeared only after FSH was added ^[4].

In a combined analysis of four clinical trials, men with hypogonadotropic hypogonadism given hCG alone achieved normal testosterone but remained azoospermic. Spermatogenesis appeared only after recombinant FSH was added, at which point 84% produced measurable sperm and 69% reached a concentration of 1.5 million/mL or higher ^[4].

Standard hCG co-therapy protocols used alongside testosterone typically do nothing to restore FSH, since hCG does not meaningfully drive the pituitary's FSH output on its own. The evidence suggests FSH support for Sertoli cell function is a required second input. A protocol that restores intratesticular testosterone through hCG alone addresses one variable in spermatogenesis and leaves another untouched.

In the randomized comparison of hCG-based therapy with GnRH pulse therapy, hCG combined with a gonadotropin carrying FSH activity produced spermatogenesis in about a quarter of treated men ^[7]. That rate was meaningfully lower than with the physiologic GnRH pulse therapy tested head to head in the same trial ^[7].

Where does the 250 to 500 IU hCG dose come from?

The 250 to 500 IU every-other-day hCG convention repeated across clinics does not trace to any trial cited below; the closest supporting data among them are dose-ranging findings in a different, hormone-deficient population ^[6].

In that population, a low-dose regimen of 500 IU three times weekly worked as well as a much higher dose ^[6]. The men were gonadotropin-deficient, not suppressed by exogenous testosterone, so the finding supports the principle of low-dose hCG without validating the every-other-day TRT schedule.

Does hCG cause weight loss?

No. A meta-analysis of controlled trials on hCG for obesity found no evidence that hCG produces weight loss, fat redistribution or reduced hunger compared with control, and it rated most underlying trials as methodologically weak ^[5].

Search results for hCG are crowded by that unrelated consumer market: very-low-calorie diet products marketed with hCG for weight loss, a use with its own regulatory scrutiny over unapproved products making weight-loss claims. The weight-loss question has nothing to do with testicular physiology and should lend no credibility, positive or negative, to the fertility-preservation discussion.

What is still unknown about hCG during TRT?

Whether hCG preserves fertility in men taking testosterone is the central open question, and it sits alongside two others:

• A fertility-endpoint trial. No randomized trial has measured pregnancy rates or semen parameters in men taking testosterone plus hCG concurrently against testosterone alone, over a period long enough to answer the pregnancy or sperm-count question directly.
• Leydig cell desensitization. Whether sustained or high-dose hCG exposure desensitizes the Leydig cell LH receptor over months to years of continuous agonist exposure has not been tested in men using hCG during testosterone administration in any study cited below. The concern is consistent with how G-protein-coupled receptors generally behave under chronic stimulation, but it remains a mechanistic hypothesis, not a demonstrated finding, and does not belong in dosing advice.
• Volume maintenance. Whether hCG keeps a previously normal testis from shrinking under TRT is extrapolated from volume recovery in hypogonadal men ^[7].